Koh Y - Search Results

1

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.

Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Among authors: koh y. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.

2

Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide.

Koh Y, Bang SM, Lee JH, Yoon HJ, Do YR, Ryoo HM, Lee N, Kim SJ, Kim K, Yoon SS, Won JH, Mun YC, Lee MH, Rhee KH, Kim HJ, Eom H, Kim MK, Shin HC; Korean Multiple Myeloma Working Party. Koh Y, et al. Ann Hematol. 2010 Feb;89(2):201-6. doi: 10.1007/s00277-009-0807-6. Epub 2009 Aug 25. Ann Hematol. 2010. PMID: 19705118

3

Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma.

Koh Y, Lim HY, Ahn JH, Lee JL, Rha SY, Kim YJ, Kim TM, Lee SH. Koh Y, et al. Ann Oncol. 2013 Apr;24(4):1026-31. doi: 10.1093/annonc/mds582. Epub 2012 Nov 23. Ann Oncol. 2013. PMID: 23180114 Free article. Clinical Trial.

4

Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.

Kim JW, Min CK, Mun YC, Park Y, Kim BS, Nam SH, Koh Y, Kwon JH, Choe PG, Park WB, Kim I. Kim JW, et al. Among authors: koh y. J Clin Virol. 2015 Dec;73:64-69. doi: 10.1016/j.jcv.2015.10.018. Epub 2015 Oct 24. J Clin Virol. 2015. PMID: 26546878

5

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party.

Kim SJ, Bang SM, Choi YS, Jo DY, Kim JS, Lee H, Eom HS, Yoon DH, Suh C, Lee JJ, Hong J, Lee JH, Koh Y, Kim K, Yoon SS, Min CK; Korean Multiple Myeloma Working Party. Kim SJ, et al. Among authors: koh y. Blood Res. 2016 Sep;51(3):193-199. doi: 10.5045/br.2016.51.3.193. Epub 2016 Sep 23. Blood Res. 2016. PMID: 27722131 Free PMC article.

6

Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications.

Shin J, Koh Y, Youk J, Kim M, Kim BS, Choi CW, Sung HJ, Park Y, Yoon SS, Kim I. Shin J, et al. Among authors: koh y. Korean J Intern Med. 2017 Jul;32(4):722-730. doi: 10.3904/kjim.2016.256. Epub 2017 Jun 26. Korean J Intern Med. 2017. PMID: 28651310 Free PMC article.

7

Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice.

Park SS, Eom HS, Kim JS, Koh Y, Choi CW, Lee JJ, Kim K, Suh C, Lee JH, Min CK; Korean Multiple Myeloma Working Party. Park SS, et al. Among authors: koh y. Jpn J Clin Oncol. 2019 Jan 1;49(1):92-95. doi: 10.1093/jjco/hyy177. Jpn J Clin Oncol. 2019. PMID: 30476124

8

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd).

Byun JM, Yoon SS, Koh Y, Min CK, Lee JH, Jo J, Park H, Lee J, Kang KW, Lee Y; and the Korean Multiple Myeloma Working Party (KMMWP). Byun JM, et al. Among authors: koh y. Ther Adv Hematol. 2020 May 12;11:2040620720921046. doi: 10.1177/2040620720921046. eCollection 2020. Ther Adv Hematol. 2020. PMID: 32523660 Free PMC article.

9

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.

Kim SJ, Lim JQ, Laurensia Y, Cho J, Yoon SE, Lee JY, Ryu KJ, Ko YH, Koh Y, Cho D, Lim ST, Enemark MB, D'Amore F, Bjerre M, Ong CK, Kim WS. Kim SJ, et al. Among authors: koh y. Blood. 2020 Dec 10;136(24):2754-2763. doi: 10.1182/blood.2020007247. Blood. 2020. PMID: 32766875 Free article. Clinical Trial.

10

Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.

Lee JH, Park Y, Kang KW, Lee JJ, Lee HS, Eom HS, Do YR, Kim JS, Yoon SS, Shin DY, Koh Y, Kim KH, Lee WS, Jo JC, Lee YJ, Lee JY, Kim DS, Shim H, Chang MH, Kim SH, Min CK; Korean multiple myeloma working party [KMMWP]. Lee JH, et al. Among authors: koh y. Ann Hematol. 2021 Aug;100(8):2051-2059. doi: 10.1007/s00277-021-04407-0. Epub 2021 Jan 15. Ann Hematol. 2021. PMID: 33447888

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,128 results

Search Page